These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CALIFORNIA
|
|
94-2424084
|
|
(State or other
jurisdiction of
incorporation or
organization)
|
|
(IRS Employer
Identification Number)
|
|
400
KATO TERRACE, FREMONT, CA
|
|
94539
|
|
(Address of
principal executive offices)
|
|
(Zip
Code)
|
|
Title
of each class
|
Trading
Symbol(s)
|
Name
of each exchange on which registered
|
|
Common Stock
|
AEHR
|
The NASDAQ Capital Market
|
|
Large accelerated
filer [ ]
|
Accelerated filer [
]
|
|
|
|
|
Non-accelerated
filer
[X]
|
Smaller reporting
company [X]
|
|
|
|
|
Emerging growth
company [ ]
|
|
|
|
|
|
|
|
|
PART II
|
|
|
|
|
|
|
|
|
|
|
|
PART III
|
|
|
|
|
|
|
|
|
|
|
|
PART IV
|
|
|
|
|
|
|
|
|
|
|
|
|
High
|
Low
|
|
Fiscal
2019:
|
|
|
|
First quarter ended August 31,
2018
|
$
2.94
|
$
2.21
|
|
Second quarter ended November 30,
2018
|
2.57
|
1.80
|
|
Third quarter ended February 28,
2019
|
1.97
|
1.03
|
|
Fourth quarter ended May 31, 2019
|
2.19
|
1.27
|
|
|
|
|
|
Fiscal
2018:
|
|
|
|
First quarter ended August 31,
2017
|
$
4.60
|
$
2.62
|
|
Second quarter ended November 30,
2017
|
4.10
|
2.50
|
|
Third quarter ended February 28,
2018
|
3.37
|
2.16
|
|
Fourth quarter ended May 31,
2018
|
2.80
|
2.12
|
|
|
Fiscal Year Ended May 31,
|
||||
|
|
2019
|
2018
|
2017
|
2016
|
2015
|
|
|
(In thousands, except per share
data)
|
||||
|
CONSOLIDATED
STATEMENTS OF OPERATIONS:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales
|
$
21,056
|
$
29,555
|
$
18,898
|
$
14,501
|
$
10,018
|
|
|
|
|
|
|
|
|
Cost of sales
|
13,454
|
17,169
|
12,118
|
9,356
|
6,180
|
|
Gross profit
|
7,602
|
12,386
|
6,780
|
5,145
|
3,838
|
|
|
|
|
|
|
|
|
Operating
expenses:
|
|
|
|
|
|
|
Selling, general and
administrative
|
7,724
|
7,290
|
7,052
|
6,975
|
6,470
|
|
Research
and development
|
4,153
|
4,181
|
4,657
|
4,324
|
4,062
|
|
Restructuring
|
725
|
--
|
--
|
--
|
--
|
|
|
|
|
|
|
|
|
Total operating
expenses
|
12,602
|
11,471
|
11,709
|
11,299
|
10,532
|
|
|
|
|
|
|
|
|
(Loss) income from operations
|
(5,000
)
|
915
|
(4,929
)
|
(6,154
)
|
(6,694
)
|
|
|
|
|
|
|
|
|
Interest expense
|
(252
)
|
(399
)
|
(678
)
|
(605
)
|
(130
)
|
|
Other income (expense), net
|
44
|
(61
)
|
(21
)
|
(16
)
|
211
|
|
|
|
|
|
|
|
|
(Loss) income before income tax (expense)
benefit
|
(5,208
)
|
455
|
(5,628
)
|
(6,775
)
|
(6,613
)
|
|
|
|
|
|
|
|
|
Income tax (expense) benefit
|
(27
)
|
73
|
(25
)
|
(10
)
|
(34
)
|
|
Net (loss) income
|
(5,235
)
|
528
|
(5,653
)
|
(6,785
)
|
(6,647
)
|
|
Less:
Net income attributable to the noncontrolling
interest
|
--
|
--
|
--
|
--
|
--
|
|
|
|
|
|
|
|
|
Net
(loss) income attributable to Aehr
Test Systems common
shareholders
|
$
(5,235
)
|
$
528
|
$
(5,653
)
|
$
(6,785
)
|
$
(6,647
)
|
|
Net
(loss) income per share:
|
|
|
|
|
|
|
Basic
|
$
(0.23
)
|
$
0.02
|
$
(0.35
)
|
$
(0.52
)
|
$
(0.55
)
|
|
Diluted
|
$
(0.23
)
|
$
0.02
|
$
(0.35
)
|
$
(0.52
)
|
$
(0.55
)
|
|
|
|
|
|
|
|
|
Shares
used in per share calculations:
|
|
|
|
|
|
|
Basic
|
22,387
|
21,732
|
16,267
|
13,091
|
12,047
|
|
Diluted
|
22,387
|
22,782
|
16,267
|
13,091
|
12,047
|
|
|
|
|
|
|
|
|
|
May 31,
|
||||
|
|
2019
|
2018
|
2017
|
2016
|
2015
|
|
CONSOLIDATED
BALANCE SHEETS:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
$
5,428
|
$
16,848
|
$
17,803
|
$
939
|
$
5,527
|
|
Working capital
|
14,522
|
18,308
|
21,494
|
4,068
|
7,776
|
|
Total assets
|
21,307
|
30,955
|
30,892
|
10,046
|
14,868
|
|
|
|
|
|
|
|
|
Long-term obligations, less current
portion
|
342
|
522
|
6,214
|
6,089
|
3,799
|
|
Total shareholders' equity
(deficit)
|
15,453
|
19,285
|
16,794
|
(723
)
|
4,550
|
|
|
Year Ended May 31,
|
||
|
|
2019
|
2018
|
2017
|
|
|
|
|
|
|
Net sales
|
100.0
%
|
100.0
%
|
100.0
%
|
|
Cost of sales
|
63.9
|
58.1
|
64.1
|
|
Gross profit
|
36.1
|
41.9
|
35.9
|
|
|
|
|
|
|
Operating
expenses:
|
|
|
|
|
Selling, general and
administrative
|
36.7
|
24.7
|
37.3
|
|
Research and development
|
19.7
|
14.1
|
24.7
|
|
Restructuring
|
3.4
|
--
|
--
|
|
|
|
|
|
|
Total operating
expenses
|
59.8
|
38.8
|
62.0
|
|
|
|
|
|
|
(Loss) income from operations
|
(23.7
)
|
3.1
|
(26.1
)
|
|
|
|
|
|
|
Interest expense
|
(1.2
)
|
(1.4
)
|
(3.6
)
|
|
Other income (expense), net
|
0.2
|
(0.2
)
|
(0.1
)
|
|
|
|
|
|
|
(Loss) income before income tax (expense)
benefit
|
(24.7
)
|
1.5
|
(29.8
)
|
|
|
|
|
|
|
Income tax (expense
)
benefit
|
(0.2
)
|
0.3
|
(0.1
)
|
|
|
|
|
|
|
Net (loss) income
|
(24.9
)
|
1.8
|
(29.9
)
|
|
Less:
Net income attributable to the noncontrolling
interest
|
--
|
--
|
--
|
|
Net (loss) income attributable to Aehr Test
Systems common shareholders
|
(24.9
)%
|
1.8
%
|
(29.9
)%
|
|
|
Payments
Due by Period (in thousands)
|
||||
|
|
|
Less
than
|
1-3
|
3-5
|
More
than
|
|
|
Total
|
1
year
|
years
|
years
|
5
years
|
|
Operating Leases
|
$
3,228
|
$
762
|
$
1,538
|
$
928
|
$
--
|
|
Purchases (1)
|
2,525
|
2,525
|
--
|
--
|
--
|
|
Total
|
$
5,753
|
$
3,287
|
$
1,538
|
$
928
|
$
--
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
May 31,
|
|
|
|
2019
|
2018
|
|
ASSETS
|
|
|
|
|
|
|
|
Current
assets:
|
|
|
|
Cash and cash
equivalents
|
$
5,428
|
$
16,848
|
|
Accounts receivable,
net
|
4,859
|
2,856
|
|
Inventories
|
9,061
|
9,049
|
|
Prepaid expenses and
other
|
686
|
703
|
|
|
|
|
|
Total current
assets
|
20,034
|
29,456
|
|
|
|
|
|
Property and equipment, net
|
1,045
|
1,203
|
|
Other assets
|
228
|
296
|
|
|
|
|
|
Total
assets
|
$
21,307
|
$
30,955
|
|
|
|
|
|
LIABILITIES
AND SHAREHOLDERS' EQUITY
|
|
|
|
|
|
|
|
Current
liabilities:
|
|
|
|
Accounts payable
|
$
1,933
|
$
1,762
|
|
Accrued expenses
|
2,034
|
1,646
|
|
Customer deposits and deferred
revenue, short
-term
|
1,545
|
1,630
|
|
Current portion of long-term
debt
|
--
|
6,110
|
|
|
|
|
|
Total current
liabilities
|
5,512
|
11,148
|
|
|
|
|
|
Deferred rent
|
153
|
63
|
|
Deferred revenue, long-term
|
189
|
459
|
|
|
|
|
|
Total
liabilities
|
5,854
|
11,670
|
|
|
|
|
|
Commitments
and contingencies (Note 17)
|
|
|
|
|
|
|
|
Aehr Test Systems shareholders' equity: Preferred
stock, $0.01 par value: Authorized: 10,000 shares; Issued and
outstanding: none
|
--
|
--
|
|
Common stock, $0.01 par value:
Authorized: 75,000 shares; Issued and outstanding: 22,669 shares
and 22,143 shares at May 31, 2019 and 2018
respectively
|
227
|
221
|
|
Additional paid-in capital
|
84,499
|
83,041
|
|
Accumulated other comprehensive
income
|
2,230
|
2,292
|
|
Accumulated deficit
|
(71,484
)
|
(66,249
)
|
|
Total Aehr Test Systems
shareholders' equity
|
15,472
|
19,305
|
|
Noncontrolling interest
|
(19
)
|
(20
)
|
|
Total shareholders'
equity
|
15,453
|
19,285
|
|
|
|
|
|
Total liabilities
and shareholders' equity
|
$
21,307
|
$
30,955
|
|
|
Year Ended May 31,
|
||
|
|
2019
|
2018
|
2017
|
|
|
|
|
|
|
Net sales
|
$
21,056
|
$
29,555
|
$
18,898
|
|
Cost of sales
|
13,454
|
17,169
|
12,118
|
|
Gross profit
|
7,602
|
12,386
|
6,780
|
|
|
|
|
|
|
Operating
expenses:
|
|
|
|
|
Selling, general and
administrative
|
7,724
|
7,290
|
7,052
|
|
Research and
development
|
4,153
|
4,181
|
4,657
|
|
Restructuring
|
725
|
--
|
--
|
|
|
|
|
|
|
Total operating
expenses
|
12,602
|
11,471
|
11,709
|
|
|
|
|
|
|
(Loss) income from operations
|
(5,000
)
|
915
|
(4,929
)
|
|
|
|
|
|
|
Interest expense
|
(252
)
|
(399
)
|
(678
)
|
|
Other income (expense), net
|
44
|
(61
)
|
(21
)
|
|
|
|
|
|
|
(Loss) income before income tax (expense)
benefit
|
(5,208
)
|
455
|
(5,628
)
|
|
|
|
|
|
|
Income tax (expense)
benefit
|
(27
)
|
73
|
(25
)
|
|
Net (loss) income
|
(5,235
)
|
528
|
(5,653
)
|
|
Less: Net income attributable to
the noncontrolling interest
|
--
|
--
|
--
|
|
|
|
|
|
|
Net (loss) income attributable to Aehr Test
Systems common shareholders
|
$
(5,235
)
|
$
528
|
$
(5,653
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net (loss) income per share – basic and
diluted
|
$
(0.23
)
|
$
0.02
|
$
(0.35
)
|
|
Shares used in per share calculation –
basic
|
22,387
|
21,732
|
16,267
|
|
Shares used in per share calculation –
diluted
|
22,387
|
22,782
|
16,267
|
|
|
Year Ended May 31,
|
||
|
|
2019
|
2018
|
2017
|
|
|
|
|
|
|
|
|
|
|
|
Net (loss)
income
|
$
(5,235
)
|
$
528
|
$
(5,653
)
|
|
|
|
|
|
|
Other comprehensive
(loss) income, net of tax:
Foreign
currency translation (loss) income
|
(61
)
|
42
|
13
|
|
|
|
|
|
|
Total comprehensive
(loss) income
|
(5,296
)
|
570
|
(5,640
)
|
|
Less: Comprehensive
income (loss) attributable to noncontrolling interest
|
1
|
(1
)
|
1
|
|
|
|
|
|
|
Comprehensive
(loss) income
, attributable to Aehr
Test Systems
|
$
(5,297
)
|
$
571
|
$
(5,641
)
|
|
|
|
|
|
|
|
Total Aehr
|
|
|
|
|
|
|
|
Accumulated
|
|
Test
|
|
|
|
|
|
|
Additional
|
Other
|
|
Systems
|
|
Total
|
|
|
Common Stock
|
Paid-in
|
Comprehensive
|
Accumulated
|
Shareholders’
|
Noncontrolling
|
Shareholders'
|
|
|
|
Shares
|
Amount
|
Capital
|
Income
|
Deficit
|
Equity (Deficit)
|
Interest
|
Equity (Deficit)
|
|
Balances, May
31, 2016
|
13,216
|
$
132
|
$
58,052
|
$
2,237
|
$
(61,124
)
|
$
(703
)
|
$
(20
)
|
$
(723
)
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common stock under employee plans
|
779
|
8
|
696
|
--
|
--
|
704
|
--
|
704
|
|
Issuance of common stock under public offering
|
4,423
|
44
|
15,788
|
--
|
--
|
15,832
|
--
|
15,832
|
|
Issuance of common stock under private
offering
|
2,722
|
27
|
5,272
|
--
|
--
|
5,299
|
--
|
5,299
|
|
Issuance
of common stock in consideration for cancellation of outstanding
vendor invoice
|
200
|
2
|
321
|
--
|
--
|
323
|
--
|
323
|
|
Stock-based
compensation
|
--
|
--
|
999
|
--
|
--
|
999
|
--
|
999
|
|
Net
loss
|
--
|
--
|
--
|
--
|
(5,653
)
|
(5,653
)
|
--
|
(5,653
)
|
|
Foreign
currency translation adjustment
|
--
|
--
|
--
|
12
|
--
|
12
|
1
|
13
|
|
|
|
|
|
|
|
|
|
|
|
Balances, May
31, 2017
|
21,340
|
213
|
81,128
|
2,249
|
(66,777
)
|
16,813
|
(19
)
|
16,794
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common stock under employee plans
|
803
|
8
|
917
|
--
|
--
|
925
|
--
|
925
|
|
Stock-based compensation
|
--
|
--
|
996
|
--
|
--
|
996
|
--
|
996
|
|
Net
income
|
--
|
--
|
--
|
--
|
528
|
528
|
--
|
528
|
|
Foreign
currency translation adjustment
|
--
|
--
|
--
|
43
|
--
|
43
|
(1
)
|
42
|
|
|
|
|
|
|
|
|
|
|
|
Balances, May
31, 2018
|
22,143
|
221
|
83,041
|
2,292
|
(66,249
)
|
19,305
|
(20
)
|
19,285
|
|
|
|
|
|
|
|
|
|
|
|
Issuance of common stock under employee plans
|
526
|
6
|
553
|
--
|
--
|
559
|
--
|
559
|
|
Stock-based compensation
|
--
|
--
|
905
|
--
|
--
|
905
|
--
|
905
|
|
Net loss
|
--
|
--
|
--
|
--
|
(5,235
)
|
(5,235
)
|
--
|
(5,235
)
|
|
Foreign
currency translation adjustment
|
--
|
--
|
--
|
(62
)
|
--
|
(62
)
|
1
|
(61
)
|
|
|
|
|
|
|
|
|
|
|
|
Balances, May
31, 2019
|
22,669
|
$
227
|
$
84,499
|
$
2,230
|
$
(71,484
)
|
$
15,472
|
$
(19
)
|
$
15,453
|
|
|
Year
Ended May 31,
|
||
|
|
2019
|
2018
|
2017
|
|
Cash
flows from operating activities:
|
|
|
|
|
Net (loss) income
|
$
(5,235
)
|
$
528
|
$
(5,653
)
|
|
Adjustments to reconcile net (loss) income to net
cash used in operating activities:
|
|
|
|
|
Stock-based compensation
expense
|
905
|
996
|
999
|
|
(Recovery of) provision for doubtful
accounts
|
(3
)
|
(58
)
|
53
|
|
Amortization of debt issuance costs
|
--
|
--
|
148
|
|
Depreciation and amortization
|
431
|
417
|
271
|
|
Changes
in operating assets and liabilities:
|
|
|
|
|
Accounts receivable
|
(2,043
)
|
1,260
|
(3,507
)
|
|
Inventories
|
(112
)
|
(2,073
)
|
430
|
|
Prepaid expenses and other
|
84
|
59
|
(707
)
|
|
Accounts payable
|
210
|
(1,095
)
|
1,686
|
|
Accrued expenses
|
402
|
62
|
53
|
|
Customer deposits and deferred
revenue
|
(355
)
|
(1,482
)
|
1,730
|
|
Deferred rent
|
90
|
63
|
--
|
|
Income taxes payable
|
(11
)
|
(28
)
|
2
|
|
Net
cash used in operating activities
|
(5,637
)
|
(1,351
)
|
(4,495
)
|
|
|
|
|
|
|
Cash
flows from investing activities:
|
|
|
|
|
Purchases of property and
equipment
|
(173
)
|
(572
)
|
(477
)
|
|
Net cash used in investing activities
|
(173
)
|
(572
)
|
(477
)
|
|
|
|
|
|
|
Cash
flows from financing activities:
|
|
|
|
|
Repayment of Convertible
Notes
|
(6,110
)
|
--
|
--
|
|
Proceeds from issuance of common stock under
public offering, net of issuance costs
|
--
|
--
|
15,832
|
|
Proceeds from issuance of common stock under
private placement, net of issuance costs
|
--
|
--
|
5,299
|
|
Proceeds from issuance of common stock under
employee plans
|
559
|
925
|
704
|
|
Net cash (used in) provided by financing
activities
|
(5,551
)
|
925
|
21,835
|
|
|
|
|
|
|
Effect of exchange rates on cash and cash
equivalents
|
(59
)
|
43
|
1
|
|
|
|
|
|
|
Net (decrease) increase in cash and cash
equivalents
|
(11,420
)
|
(955
)
|
16,864
|
|
|
|
|
|
|
Cash and cash equivalents, beginning of
year
|
16,848
|
17,803
|
939
|
|
Cash and cash equivalents, end of
year
|
$
5,428
|
$
16,848
|
$
17,803
|
|
|
|
|
|
|
Supplemental
cash flow information:
|
|
|
|
|
Cash
paid during the year for:
|
|
|
|
|
Income taxes
|
$
37
|
$
37
|
$
18
|
|
Interest
|
$
610
|
$
550
|
$
516
|
|
|
|
|
|
|
Supplemental
disclosure of non-cash flow information:
|
|
|
|
|
Fair value of common stock issued to settle
accounts payable
|
$
--
|
$
--
|
$
323
|
|
Net transfer of equipment between inventory and
property and equipment
|
$
119
|
$
--
|
$
--
|
|
Furniture
and fixtures
|
2 to 6
years
|
|
Machinery
and equipment
|
3 to 6
years
|
|
Test
equipment
|
4 to 6
years
|
|
|
Year Ended May 31,
|
||
|
|
2019
|
2018
|
2017
|
|
Type
of good / service:
|
|
|
|
|
Systems
|
$
9,566
|
$
18,174
|
$
12,115
|
|
Contactors
|
6,154
|
6,500
|
1,991
|
|
Services
|
5,336
|
4,881
|
4,792
|
|
|
$
21,056
|
$
29,555
|
$
18,898
|
|
Product
lines:
|
|
|
|
|
Wafer-level
|
$
14,618
|
$
13,080
|
$
9,582
|
|
Test During Burn-In
|
6,438
|
16,475
|
9,316
|
|
|
$
21,056
|
$
29,555
|
$
18,898
|
|
|
Year Ended May 31,
|
||
|
|
2019
|
2018
|
2017
|
|
Geographic
region:
|
|
|
|
|
United States
|
$
13,468
|
$
8,446
|
$
7,762
|
|
Asia
|
5,648
|
19,973
|
10,439
|
|
Europe
|
1,940
|
1,136
|
697
|
|
|
$
21,056
|
$
29,555
|
$
18,898
|
|
|
Year Ended May 31,
|
||
|
|
2019
|
2018
|
2017
|
|
Timing
of revenue recognition (in thousands):
|
|
|
|
|
Products and services transferred at a point in
time
|
$
18,473
|
$
27,337
|
$
17,193
|
|
Services transferred over time
|
2,583
|
2,218
|
1,705
|
|
|
$
21,056
|
$
29,555
|
$
18,898
|
|
|
Year Ended May 31,
|
||
|
|
2019
|
2018
|
2017
|
|
Numerator: Net (loss) income
|
$
(5,235
)
|
$
528
|
$
(5,653
)
|
|
|
|
|
|
|
Denominator
for basic net (loss) income per share:
|
|
|
|
|
Weighted-average shares
outstanding
|
22,387
|
21,732
|
16,267
|
|
|
|
|
|
|
Shares used in basic net (loss) income per share
calculation
|
22,387
|
21,732
|
16,267
|
|
|
|
|
|
|
Effect of dilutive securities
|
--
|
1,050
|
--
|
|
|
|
|
|
|
|
|
|
|
|
Denominator for diluted net (loss) income per
share
|
22,387
|
22,782
|
16,267
|
|
|
|
|
|
|
Basic net (loss) income per
share
|
$
(0.23
)
|
$
0.02
|
$
(0.35
)
|
|
|
|
|
|
|
Diluted net (loss) income per share
|
$
(0.23
)
|
$
0.02
|
$
(0.35
)
|
|
|
Balance as of
|
|
|
|
|
|
May 31, 2019
|
Level 1
|
Level 2
|
Level 3
|
|
Money market funds
|
$
3,017
|
$
3,017
|
$
--
|
$
--
|
|
Assets
|
$
3,017
|
$
3,017
|
$
--
|
$
--
|
|
|
Balance as of
|
|
|
|
|
|
May 31, 2018
|
Level 1
|
Level 2
|
Level 3
|
|
Money market funds
|
$
7,813
|
$
7,813
|
$
--
|
$
--
|
|
U.S. Treasury securities
|
5,983
|
5,983
|
--
|
--
|
|
Assets
|
$
13,796
|
$
13,796
|
$
--
|
$
--
|
|
|
May 31,
|
|
|
|
2019
|
2018
|
|
Accounts receivable
|
$
4,859
|
$
2,860
|
|
Less: Allowance for doubtful
accounts
|
--
|
(4
)
|
|
|
$
4,859
|
$
2,856
|
|
|
|
Additions
|
|
|
|
|
Balance at
|
charged to
|
|
Balance
|
|
|
beginning
|
costs and
|
|
at end
|
|
|
of year
|
expenses
|
Deductions*
|
of year
|
|
Allowance
for doubtful accounts receivable:
May 31,
2019
|
$
4
|
$
--
|
$
(4
)
|
$
--
|
|
|
|
|
|
|
|
May 31,
2018
|
$
61
|
$
4
|
$
(61
)
|
$
4
|
|
|
|
|
|
|
|
|
May 31,
|
|
|
(In
Thousands)
|
2019
|
2018
|
|
Raw materials and
sub-assemblies
|
$
5,471
|
$
5,747
|
|
Work in process
|
3,580
|
3,068
|
|
Finished goods
|
10
|
234
|
|
|
$
9,061
|
$
9,049
|
|
|
May 31,
|
|
|
(In
Thousands)
|
2019
|
2018
|
|
Leasehold improvements
|
$
1,154
|
$
1,154
|
|
Furniture and fixtures
|
983
|
984
|
|
Machinery and equipment
|
3,097
|
2,865
|
|
Test equipment
|
2,604
|
2,595
|
|
|
7,838
|
7,598
|
|
Less: Accumulated depreciation and
amortization
|
(6,793
)
|
(6,395
)
|
|
|
$
1,045
|
$
1,203
|
|
|
May 31,
|
|
|
(In
Thousands)
|
2019
|
2018
|
|
Payroll related
|
$
990
|
$
1,014
|
|
Restructuring
|
408
|
--
|
|
Commissions and bonuses
|
168
|
101
|
|
Professional services
|
162
|
163
|
|
Warranty
|
154
|
135
|
|
Material purchases
|
65
|
--
|
|
Taxes payable
|
29
|
34
|
|
Investor relations
|
19
|
19
|
|
Accrued interest
|
--
|
139
|
|
Other
|
39
|
41
|
|
|
$
2,034
|
$
1,646
|
|
|
May 31,
|
|
|
(In
Thousands)
|
2019
|
2018
|
|
Customer deposits
|
$
1,003
|
$
1,340
|
|
Deferred revenue
|
542
|
290
|
|
|
$
1,545
|
$
1,630
|
|
|
Year Ended May 31,
|
||
|
|
2019
|
2018
|
2017
|
|
Domestic
|
$
(5,273
)
|
$
433
|
$
(5,663
)
|
|
Foreign
|
65
|
22
|
35
|
|
|
$
(5,208
)
|
$
455
|
$
(5,628
)
|
|
|
Year Ended May 31,
|
||
|
|
2019
|
2018
|
2017
|
|
Federal
income taxes:
|
|
|
|
|
Current
|
$
--
|
$
99
|
$
--
|
|
Deferred
|
--
|
--
|
--
|
|
State
income taxes:
|
|
|
|
|
Current
|
(6
)
|
(22
)
|
(8
)
|
|
Deferred
|
--
|
--
|
--
|
|
Foreign
income taxes:
|
|
|
|
|
Current
|
(21
)
|
(4
)
|
(17
)
|
|
Deferred
|
--
|
--
|
--
|
|
|
$
(27
)
|
$
73
|
$
(25
)
|
|
|
Year Ended May 31,
|
||
|
|
2019
|
2018
|
2017
|
|
U.S. federal statutory tax rate
|
21.0
%
|
28.6
%
|
34.0
%
|
|
State taxes, net of federal tax
effect
|
(1.0
)
|
(16.7
)
|
(0.1
)
|
|
Foreign rate differential
|
(0.7
)
|
39.4
|
0.1
|
|
Stock-based compensation
|
(2.8
)
|
39.9
|
(2.8
)
|
|
Research and development credit
|
1.5
|
5.9
|
3.1
|
|
Change in valuation allowance
|
(15.6
)
|
(1,349.2
)
|
(33.8
)
|
|
Federal rate change impact
|
--
|
1,419.7
|
--
|
|
Federal AMT refund
|
--
|
(20.0
)
|
--
|
|
ASU 2016-09 adoption
|
--
|
(169.1
)
|
--
|
|
Other
|
(2.9
)
|
5.4
|
(0.9
)
|
|
Effective tax rate
|
(0.5
)%
|
(16.1
)%
|
(0.4
)%
|
|
|
Year Ended May 31,
|
|
|
|
2019
|
2018
|
|
|
|
|
|
Net operating losses
|
$
13,475
|
$
12,918
|
|
Credit carryforwards
|
4,995
|
4,952
|
|
Inventory reserves
|
790
|
588
|
|
Reserves and accruals
|
1,379
|
1,419
|
|
Other
|
298
|
247
|
|
|
|
|
|
|
20,937
|
20,124
|
|
|
|
|
|
Less: Valuation allowance
|
(20,937
)
|
(20,124
)
|
|
Net deferred tax assets
|
$
--
|
$
--
|
|
Beginning balance as of May 31,
2016
|
$
789
|
|
|
|
|
Decreases related to prior year tax
positions
|
--
|
|
Decreases related to lapse of statute of
limitations
|
--
|
|
|
|
|
Balance at May 31, 2017
|
$
789
|
|
|
|
|
Increases related to prior year tax
positions
|
889
|
|
Increases related to current year tax
positions
|
107
|
|
|
|
|
Balance at May 31, 2018
|
$
1,785
|
|
|
|
|
Decreases related to prior year tax
positions
|
(41
)
|
|
Increases related to current year tax
positions
|
65
|
|
|
|
|
Balance at May 31, 2019
|
$
1,809
|
|
|
Cumulative Translation Adjustments
|
Unrealized Loss on Investments, Net
|
Total
|
|
|
|
|
|
|
Balance at May 31, 2017
|
$
2,249
|
$
--
|
$
2,249
|
|
Other comprehensive income (loss) before
reclassifications
|
43
|
--
|
43
|
|
Amounts reclassified out of
AOCI
|
--
|
--
|
--
|
|
Other comprehensive income (loss), net of
tax
|
43
|
--
|
43
|
|
Balance at May 31, 2018
|
$
2,292
|
$
--
|
$
2,292
|
|
Other comprehensive income (loss) before
reclassifications
|
(62
)
|
--
|
(62
)
|
|
Amounts reclassified out of
AOCI
|
--
|
--
|
--
|
|
Other comprehensive income (loss), net of
tax
|
(62
)
|
--
|
(62
)
|
|
Balance at May 31, 2019
|
$
2,230
|
$
--
|
$
2,230
|
|
|
Year Ended May 31,
|
||
|
|
2019
|
2018
|
2017
|
|
Stock-based
compensation in the form of stock options, RSUs, and ESPP purchase
rights, included in:
|
|
|
|
|
|
|
|
|
|
Cost of sales
|
$
104
|
$
148
|
$
91
|
|
Selling, general and
administrative
|
545
|
592
|
714
|
|
Research and development
|
256
|
256
|
194
|
|
|
|
|
|
|
Net effect on net income
(loss)
|
$
905
|
$
996
|
$
999
|
|
|
|
|
|
|
Effect
on net income (loss) per share:
|
|
|
|
|
Basic
|
$
0.04
|
$
0.05
|
$
0.06
|
|
Diluted
|
$
0.04
|
$
0.04
|
$
0.06
|
|
|
Year Ended May 31,
|
||
|
|
2019
|
2018
|
2017
|
|
|
|
|
|
|
Expected term (in years)
|
5
|
4
|
4
|
|
Volatility
|
0.72
|
0.77
|
0.81
|
|
Risk-free interest rates
|
2.83
%
|
1.95
%
|
1.02
%
|
|
Weighted-average grant date fair
value
|
$
1.33
|
$
2.07
|
$
1.09
|
|
|
Year End May 31,
|
||
|
|
2019
|
2018
|
2017
|
|
|
|
|
|
|
Expected term (in years)
|
0.5 – 2.0
|
0.5 – 2.0
|
0.5 – 2.0
|
|
Volatility
|
0.48 – 0.78
|
0.56 – 0.81
|
0.79 – 1.08
|
|
Risk-free interest rates
|
2.33%-2.82
%
|
1.92%-2.25
%
|
0.48%-0.80
%
|
|
Weighted-average grant date fair
value
|
$
1.14
|
$
1.01
|
$
1.65
|
|
|
Available
|
|
|
Shares
|
|
Balance, May 31, 2016
|
1,847
|
|
|
|
|
Additional shares reserved
|
2,238
|
|
Options granted
|
(368
)
|
|
RSUs granted
|
(157
)
|
|
Options terminated
|
55
|
|
Plan shares expired
|
(1,446
)
|
|
|
|
|
Balance, May 31, 2017
|
2,169
|
|
|
|
|
Options granted
|
(338
)
|
|
RSUs granted
|
(64
)
|
|
RSUs cancelled
|
33
|
|
Options terminated
|
16
|
|
Plan shares expired
|
(4
)
|
|
|
|
|
Balance, May 31, 2018
|
1,812
|
|
|
|
|
Options granted
|
(804
)
|
|
RSUs cancelled
|
8
|
|
Options terminated
|
195
|
|
Plan shares expired
|
(64
)
|
|
|
|
|
Balance, May 31, 2019
|
1,147
|
|
|
Outstanding Options
|
||
|
|
|
Weighted
|
|
|
|
Number
|
Average
|
Aggregate
|
|
|
of
|
Exercise
|
Intrinsic
|
|
|
Shares
|
Price
|
Value
|
|
Balances, May 31, 2016
|
3,201
|
$
1.66
|
$
189
|
|
|
|
|
|
|
Options granted
|
368
|
$
1.83
|
|
|
Options terminated
|
(55
)
|
$
1.42
|
|
|
Options exercised
|
(440
)
|
$
1.35
|
|
|
|
|
|
|
|
Balances, May 31, 2017
|
3,074
|
$
1.73
|
$
8,763
|
|
|
|
|
|
|
Options granted
|
338
|
$
3.56
|
|
|
Options terminated
|
(16
)
|
$
2.72
|
|
|
Options exercised
|
(537
)
|
$
1.17
|
|
|
|
|
|
|
|
Balances, May 31, 2018
|
2,859
|
$
2.04
|
$
1,987
|
|
|
|
|
|
|
Options granted
|
804
|
$
2.19
|
|
|
Options terminated
|
(195
)
|
$
2.32
|
|
|
Options exercised
|
(361
)
|
$
0.85
|
|
|
|
|
|
|
|
Balances, May 31, 2019
|
3,107
|
$
2.20
|
$
283
|
|
|
|
|
|
|
Options
fully vested and expected to vest at May 31, 2019
|
3,079
|
$
2.20
|
$
282
|
|
|
Options
Outstanding
|
Options
Exercisable
|
|||||
|
|
at
May 31, 2019
|
at
May 31, 2019
|
|||||
|
Range of
Exercise
Prices
|
Number Outstanding
Shares
|
Weighted Average Remaining
Contractual Life (Years)
|
Weighted Average
Exercise Price
|
Number Exercisable
Shares
|
Weighted Average
Remaining Contractual Life (Years)
|
Weighted Average
Exercise Price
|
Aggregate Intrinsic
Value
|
|
$
0.80-$0.97
|
47
|
0.52
|
$
0.85
|
47
|
0.52
|
$
0.85
|
-
|
|
$
1.09-$1.28
|
456
|
0.78
|
$
1.28
|
456
|
0.78
|
$
1.28
|
|
|
$
1.65-$2.06
|
761
|
4.57
|
$
1.83
|
427
|
3.50
|
$
1.79
|
|
|
$
2.10-$2.81
|
1,600
|
3.55
|
$
2.43
|
1,244
|
2.81
|
$
2.44
|
|
|
$
3.46-$3.93
|
243
|
5.16
|
$
3.85
|
140
|
5.20
|
$
3.79
|
|
|
|
|
|
|
|
|
|
|
|
$
0.80-$3.93
|
3,107
|
3.47
|
$
2.20
|
2,314
|
2.64
|
$
2.14
|
$
274
|
|
|
Year Ended May 31,
|
||
|
|
2019
|
2018
|
2017
|
|
Foreign exchange gain (loss)
|
$
43
|
$
(63
)
|
$
(21
)
|
|
Other income, net
|
1
|
2
|
--
|
|
|
$
44
|
$
(61
)
|
$
(21
)
|
|
|
May 31,
|
|
|
|
2019
|
2018
|
|
|
|
|
|
Balance at the beginning of the
year
|
$
135
|
$
113
|
|
Accruals for warranties issued during the
year
|
214
|
329
|
|
Consumption of reserves
|
(195
)
|
(307
)
|
|
|
|
|
|
Balance at the end of the year
|
$
154
|
$
135
|
|
|
May
31,
|
|
|
|
2019
|
2018
|
|
United
States
|
$
1,005
|
$
1,156
|
|
Asia
|
40
|
40
|
|
Europe
|
--
|
7
|
|
|
$
1,045
|
$
1,203
|
|
Years
Ending May 31,
|
|
|
2020
|
$
762
|
|
2021
|
766
|
|
2022
|
772
|
|
2023
|
795
|
|
2024
|
133
|
|
Thereafter
|
--
|
|
Total
|
$
3,228
|
|
|
Three Months Ended
|
|||
|
|
Aug. 31,
|
Nov. 30,
|
Feb. 28,
|
May 31,
|
|
|
2018
|
2018
|
2019
|
2019
|
|
Net sales
|
$
4,740
|
$
5,911
|
$
3,163
|
$
7,242
|
|
Gross profit
|
$
1,553
|
$
2,398
|
$
272
|
$
3,379
|
|
Net (loss) income
|
$
(1,515
)
|
$
(629
)
|
$
(3,201
)
|
$
110
|
|
Net (loss) income per share basic and
diluted
|
$
(0.07
)
|
$
(0.03
)
|
$
(0.14
)
|
$
0.00
|
|
|
Three Months Ended
|
|||
|
|
Aug. 31,
|
Nov. 30,
|
Feb. 28,
|
May 31,
|
|
|
2017
|
2017
|
2018
|
2018
|
|
Net sales
|
$
6,970
|
$
7,923
|
$
7,393
|
$
7,269
|
|
Gross profit
|
$
2,918
|
$
3,131
|
$
3,176
|
$
3,161
|
|
Net income
|
$
10
|
$
60
|
$
267
|
$
191
|
|
Net income per share basic and diluted
|
$
0.00
|
$
0.00
|
$
0.01
|
$
0.01
|
|
Exhibit
Number
|
|
Description
|
|||||||||
|
3.1
(1)
|
|
Restated
Articles of Incorporation of Registrant.
|
|||||||||
|
|
Amended
and Restated Bylaws of Registrant.
|
||||||||||
|
4.1
(2)
|
|
Form
of Common Stock certificate.
|
|||||||||
|
4.7
(3)
|
|
Registration
Rights Agreement by and among the Company and the
Investors
(as defined therein), dated as of September 22, 2016.
|
|||||||||
|
10.1
(4)
|
|
2006
Equity Incentive Plan.*
|
|||||||||
|
10.2
(5)
|
|
Amended
and Restated 2006 Employee Stock Purchase Plan.*
|
|||||||||
|
10.3
(6)
|
|
2016
Equity Incentive Plan.*
|
|||||||||
|
10.4
(7)
|
|
Form
of Indemnification Agreement entered into between Registrant
and
its directors and executive officers.*
|
|||||||||
|
10.5
(8)
|
|
Form
of Change of Control Agreement.*
|
|||||||||
|
10.6
(9)
|
|
Lease
dated August 3, 1999 for facilities located at Building C,
400
Kato Terrace, Fremont, California.
|
|||||||||
|
10.6.1
(10)
|
|
First
Amendment dated May 06, 2008 for facilities located at
400
Kato Terrace, Fremont, California.
|
|||||||||
|
10.6.2
(11)
|
|
Second
Amendment dated November 7, 2014 for facilities located at
400 Kato Terrace, Fremont, California.
|
|||||||||
|
10.6.3
(12)
|
|
Third
Amendment dated February 27, 2018 for facilities located at
400
Kato Terrace, Fremont, California.
|
|||||||||
|
10.10
(13)
|
|
Offer
Letter dated January 3, 2012, between the Company and Gayn
Erickson.*
|
|||||||||
|
10.11
(14)
|
|
Offer
Letter dated March 5, 2013, between the Company and Rhea
Posedel.*
|
|||||||||
|
10.12
(15)
|
|
Change
of Control Severance Agreement dated January 3, 2012, between the
Company and Gayn Erickson.*
|
|||||||||
|
10.13
(16)
|
|
Amended and Restated Change of Control Severance Agreement dated
March 5, 2013, between the Company and Rhea J.
Posedel.*
|
|||||||||
|
10.15
(17)
|
|
Form
of 2006 Equity Incentive Plan Stock Option Award Agreement.*
|
|||||||||
|
10.16
(18)
|
|
Form
of 2006 Equity Incentive Plan Restricted Stock Unit Award.*
|
|||||||||
|
10.17
(19)
|
|
Form
of 2016 Equity Incentive Plan Stock Option Award Agreement.*
|
|||||||||
|
10.18
(20)
|
|
Form
of 2016 Equity Incentive Plan Restricted Stock Unit Award.*
|
|||||||||
|
10.19
(21)
|
|
Purchase
Agreement by and among the Company and the Investors (as
defined
therein), dated as of September 22, 2016.
|
|||||||||
|
10.21
(22)
|
|
Underwriting
Agreement dated April 13, 2017, between the Company and
Craig-Hallum Capital Group LLLC
|
|||||||||
|
|
Subsidiaries
of the Company.
|
||||||||||
|
|
Consent
of BPM LLP - Independent Registered Public Accounting Firm
(filed
herewith).
|
||||||||||
|
|
Power
of Attorney (incorporated by reference to the signature page of
this Annual Report on Form 10-K).
|
||||||||||
|
|
Certification
Statement of Chief Executive Officer pursuant to Section 302(a) of
the Sarbanes-Oxley Act of 2002 (filed herewith).
|
|
|
|
Certification
Statement of Chief Financial Officer pursuant to Section 302(a) of
the Sarbanes-Oxley Act of 2002 (filed herewith).
|
|
|
Certification
of Chief Executive Officer and Chief Financial Officer pursuant to
18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002 (furnished herewith).
|
|
|
101.INS
|
|
XBRL
Instance Document
|
|
101.SCH
|
|
XBRL
Taxonomy Extension Schema Document
|
|
101.CAL
|
|
XBRL
Taxonomy Extension Calculation Linkbase Document
|
|
101.DEF
|
|
XBRL
Taxonomy Extension Definition Linkbase Document
|
|
101.LAB
|
|
XBRL
Taxonomy Extension Label Linkbase Document
|
|
101.PRE
|
|
XBRL
Taxonomy Extension Presentation Linkbase Document
|
|
|
AEHR
TEST SYSTEMS
|
|
|
|
|
|
|
|
|
Dated:
August 28, 2019
|
By:
|
/s/
GAYN ERICKSON
|
|
|
|
|
Gayn
Erickson
|
|
|
|
|
PRESIDENT
AND CHIEF EXECUTIVE OFFICER
|
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
|
|
|
|
President,
Chief Executive Officer, and Director
|
|
|
|
/s/
GAYN ERICKSON
|
|
(Principal
Executive Officer)
|
|
August
28, 2019
|
|
Gayn Erickson
|
|
|
|
|
|
|
|
Vice President of Finance
and Chief Financial Officer
|
|
|
|
/s/
KENNETH B. SPINK
|
|
(Principal
Financial and Accounting Officer)
|
|
August
28, 2019
|
|
Kenneth B. Spink
|
|
|
|
|
|
|
|
|
|
|
|
/s/
LAURA OLIPHANT
|
|
Director
|
|
August
28, 2019
|
|
Laura
Oliphant
|
|
|
|
|
|
|
|
|
|
|
|
/s/
RHEA J. POSEDEL
|
|
Chairman
|
|
August 28,
2019
|
|
Rhea J.
Posedel
|
|
|
|
|
|
|
|
|
|
|
|
/s/
MARIO M. ROSATI
|
|
Director
|
|
August
28, 2019
|
|
Mario M. Rosati
|
|
|
|
|
|
|
|
|
|
|
|
/s/
JOHN M. SCHNEIDER
|
|
Director
|
|
August
28, 2019
|
|
John M. Schneider
|
|
|
|
|
|
|
|
|
|
|
|
/s/
HOWARD T. SLAYEN
|
|
Director
|
|
August
28, 2019
|
|
Howard T. Slayen
|
|
|
|
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|